As a treating physician who also serves as the Chairman of the Alliance for Safe Biologic Medicines (ASBM), I have been watching with great interest as the Food and Drug Administration (FDA) begins to unveil the approach it will take to bring “biosimilar” medications to the US. Biosimilars are attempts to replicate brand name biologic medicines. But as the name indicates, they are similar to them but not identical. Interestingly, when you look up the definition for “identical” in the dictionary it reminds us that it means to “have such a near similarity or resemblance as to be essentially equal or interchangeable.”

Read More